This case was reported in a literature article and described the occurrence of uveitis in a subject who received DTP (A or W not  known) vaccine.   On an unknown date, an unknown time after receiving simultaneously  DTP (A or W not known) vaccine  and pertussis vaccine, the subject developed uveitis. Serious criteria included GSK medically significant. The outcome of uveitis was unknown. Co-suspect product included pertussis vaccine which led to an overdose. The investigator considered that there was a  reasonable possibility that the uveitis may have been caused by DTP  (A or W not known) vaccine. Additional  information  was  provided: This case was reported in a literature article and described the occurrence of vaccine-associated uveitis in a patient  aged between 2 months  and 86 years of unspecified gender who was vaccinated with unspecified DPT (acellular or whole cell) and pertussis  vaccines (manufacturer unknown for both). This case has been mentioned in table 2 in the literature article.  The patient was part of observational study conducted to collect data on cases  of vaccine-associated uveitis reported from 1984 to 2014 to three spontaneous reporting databases on adverse drug events.  In addition, a literature search was performed using the keywords of uveitis, iritis, iridocyclitis, or  vitritis,  in combination with vaccines, hepatitis A, hepatitis B, HPV, Bacillus Calmette-Guerin (BCG), Brucella, DPT, herpes, influenza, MMR, pneumococcal, smallpox, tetanus, typhoid, Heine Medin, varicella, yellow fever, and zoster vaccine.  In this study, out of 289 patients of vaccine associated uveitis, 199 patients were females, 77 were males and in 13 patients gender was not reported. No information on patient's medical history or family history or concomitant medication or concurrent condition was provided. On an unspecified date, the patient received unspecified DPT (acellular or whole cell) and pertussis vaccines simultaneously (administration route and site unspecified; dosages unknown; batch number not provided for both)  which  led  to  an  overdose  of  pertussis  vaccine.  (Information on which dose  of a particular vaccine was associated with uveitis was not available in the reporting systems.)  On an unspecified date between 1984 and 2014, between 1 day  and 6 years  after vaccination with unspecified DPT (acellular or whole  cell)  and pertussis vaccines, the patient developed uveitis. Treatment was unknown. The outcome for the event was unknown.  The authors considered the event  of uveitis associated to unspecified DPT (acellular or whole cell) and pertussis vaccines. The authors concluded "While uveitis may be a rare adverse effect of vaccines, awareness of this potential reaction to  vaccines is important, as is reporting such occurrences to adverse drug reaction registries. That hepatitis B vaccine accounted for a disproportionate number of cases certainly piques curiosity about contributing factors for uveitis in association with hepatitis B vaccine. In a similar vein, we are also left with the question of why a disproportionate number of cases of vaccine-associated uveitis occur in females (199 in females versus 77 in males in our data). Future studies of vaccine-associated uveitis could focus on active surveillance and rigorous clinical evaluation of patients presenting with uveitis temporally related to vaccination". This is 1 of 14 valid cases reported in the same literature article. This article is not available for regulatory submission due to copyright restriction.